PharVision Advisers’s QuinStreet QNST Stock Holding History

PharVision Advisers’s Portfolio QNST Stock Details QNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,617	Closed	-$368K	–	525
2025 Q4	$368K	Buy	25,617 +8,507	+50%	+$123K	0.19%	154
2025 Q3	$265K	Buy	17,110 +4,925	+40%	+$78.2K	0.15%	301
2025 Q2	$196K	Buy	+12,185	New	+$195K	0.28%	207
2025 Q1	–	Sell	-17,555	Closed	-$405K	–	473
2024 Q4	$405K	Buy	+17,555	New	+$369K	0.34%	75

Other funds holding QNST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCMF

Private Capital Management (Florida) Naples, Florida $1B AUM 15.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PharVision Advisers's QNST Position: Q1 2026 in Review

PharVision Advisers sold out of QuinStreet (QNST) in Q1 2026, closing a stake of 25,617 shares — an estimated $368K sold.

PharVision Advisers first reported a position in QNST in Q4 2024 and held it in 4 quarters. The position peaked at $405K in Q4 2024. 220 funds tracked by Wall St. Rank hold QNST as of Q1 2026.

PharVision Advisers reported no remaining QuinStreet position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 25,617 QuinStreet shares in Q1 2026, an estimated $368K.
PharVision Advisers first reported a position in QuinStreet in Q4 2024 and held it in 4 quarters.
PharVision Advisers's QuinStreet position peaked at $405K in Q4 2024.
220 funds tracked by Wall St. Rank held QuinStreet as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.